Eric Easom

All filings by Eric Easom on record concern AN2 Therapeutics, Inc., in the capacity of chief executive. The record holds 31 filings, for trades running from 29 March 2022 to 20 February 2026.

The open-market side counts 3 purchases for €106k alongside 23 sales for €1.6M. Netting one side against the other leaves €1.5M of net selling. Unlike grants, an open-market purchase is paid for by the insider, at the market price. The rest of the record consists of 4 share grants.

A typical purchase (the median) is worth €47k. On 1 out of 3 purchases, another insider of the same company was buying within the same 30 days. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time.

Most recently, on 23 February 2026, the filings show a share grant in AN2 Therapeutics, Inc. The clock since the last published purchase (3 June 2025) now reads 508 days. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. Section 16 rules allow two business days to file each Form 4. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.